CYP19A1 and breast cancer: Aromatase inhibitors (AIs), blocking endogenous estrogen synthesis through the inhibition of peripheral aromatase, represent the gold standard adjuvant hormone therapy for postmenopausal women with hormone receptor-positive BC.